Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Thrombocytopenia Associated with Increase in Disease Severity and Mortality in COVID-19 Patients

Ranjit Banwait, MD, Aya Marachi, MD, Uma G. Iyer, MD

Blood (2020) 136 (Supplement 1): 1.

https://doi.org/10.1182/blood-2020-143167

Published: 2020

Journal Articles

Final Results of the Phase I/II Study of Chemosensitization Using the CXCR4 Inhibitor Plerixafor in Combination with Bortezomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma

Blood (2015) 126 (23): 4256.

https://doi.org/10.1182/blood.V126.23.4256.4256

Published: 2015

Journal Articles

Final Results of Phase I/II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Combination with Bortezomib and Rituximab (RVR) in Relapsed or Refractory Waldenstrom Macroglobulinemia

Irene M. Ghobrial, MD, Robert Allyn Redd, MS, Jeffrey Matous, Philippe Armand, MD PhD, Erica N Boswell, BS, Stacey Chuma, BSN, Kimberly Noonan, RN, NP, AOCN, Megan H. MacNabb, BA, Ranjit Banwait, Courtney Hanlon, Houry Leblebjian, PharmD, BCOP, Diane Warren, Jorge J. Castillo, MD, Jacob P. Laubach, MD, Claudia E. Paba-Prada, MD, Kenneth C. Anderson, MD, Paul G. Richardson, Edie A. Weller, PhD, Steven P Treon, MD MA, PhD

Blood (2014) 124 (21): 3081.

https://doi.org/10.1182/blood.V124.21.3081.3081

Published: 2014

Journal Articles

Phase I/II Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy In Relapsed Or Relapsed/Refractory Multiple Myeloma

Irene M. Ghobrial, MD, Kenneth Shain, MD, PhD, Courtney Hanlon, Ranjit Banwait, Abdel Kareem Azab, Bpharm, PhD, Jacob P. Laubach, MD, Philippe Armand, MD, PhD, Nikhil C. Munshi, MD, Robert L Schlossman, MD, Stacey Chuma, BSN, Erica N Boswell, BS, Patrick Mostyn, Leblebjian Houry, PharmD, Kenneth C. Anderson, MD, Paul G. Richardson, MD

Blood (2013) 122 (21): 1947.

https://doi.org/10.1182/blood.V122.21.1947.1947

Published: 2013

Journal Articles

Mirna Expression Profiling and Proteomic Analysis Of Circulating Exosomes From Multiple Myeloma Patients

Salomon Manier, MD, Erica N Boswell, BS, Siobhan Glavey, MD, Antonio Sacco, BS, Patricia Maiso, PhD, Yuji Mishima, PhD, Yosra Aljaway, BS, Ranjit Banwait, MA, Wenjing Zhang, MD, Yu Zhang, MD, Ilyas Sahin, MD, Michele Moschetta, MD, Yong Zhang, PhD, Michaela R Reagan, PhD, John M. Asara, PhD, Xavier Leleu, MD, PhD, Aldo M Roccaro, MD, PhD, Irene M. Ghobrial, MD

Blood (2013) 122 (21): 3086.

https://doi.org/10.1182/blood.V122.21.3086.3086

Published: 2013

Journal Articles

Extramedullary Disease In Waldenstrom’s Macroglobulinemia

Ranjit Banwait, MA, Yosra Aljawai, MS, Joseph Cappuccio, Serena McDiarmid, Salomon Manier, MD, Steven Peter Treon, MD, MA, PhD, Irene M. Ghobrial, MD

Blood (2013) 122 (21): 1773.

https://doi.org/10.1182/blood.V122.21.1773.1773

Published: 2013

Journal Articles

Phase I/II Trial Of Everolimus, Bortezomib and Rituximab In Relapsed Or Relapsed/Refractory Waldenstrom's Macroglobulinemia

Irene M. Ghobrial, MD, Erica N Boswell, BS, Stacey Chuma, BSN, Ranjit Banwait, Courtney Hanlon, Houry Leblebjian, PharmD, BCOP, Diane Warren, Patrick Mostyn, Farzana Masood, Paul G. Richardson, MD, Steven Peter Treon, MD, MA, PhD, Jeffrey Matous, MD

Blood (2013) 122 (21): 4402.

https://doi.org/10.1182/blood.V122.21.4402.4402

Published: 2013

Journal Articles

Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemia

Irene M. Ghobrial, Federico Campigotto, Timothy J. Murphy, Erica N. Boswell, Ranjit Banwait, Feda Azab, Stacey Chuma, Janet Kunsman, Amanda Donovan, Farzana Masood, Diane Warren, Scott Rodig, Kenneth C. Anderson, Paul G. Richardson, Edie Weller, Jeffrey Matous

Blood (2013) 121 (8): 1296–1303.

https://doi.org/10.1182/blood-2012-06-439307

Published: 2013

Journal Articles

Comparative miRNA Expression Profiling of Circulating Exosomes From MGUS and Smoldering Multiple Myeloma Patients

Salomon Manier, MD, Erica N Boswell, BS, Antonio Sacco, BS, Patricia Maiso, PhD, Ranjit Banwait, MA, Yosra Aljawai, BS, Xavier Leleu, MD, PhD, Aldo M Roccaro, MD, PhD, Irene M. Ghobrial, MD

Blood (2012) 120 (21): 3975.

https://doi.org/10.1182/blood.V120.21.3975.3975

Published: 2012

Journal Articles

Phase I Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy in Relapsed or Relapsed/Refractory Multiple Myeloma

Irene M. Ghobrial, MD, Ranjit Banwait, MA, Abdel Kareem Azab, Bpharm, PhD, Phong Quang, BS, Jacob P. Laubach, MD, Amanda Donovan, BS, Meghan Bagshaw, Philippe Armand, MD, PhD, Nikhil C. Munshi, MD, Robert L. Schlossman, MD, Stacey Chuma, BSN, Janet Kunsman, NP, Diane Warren, Kenneth C. Anderson, MD, Paul G. Richardson, MD

Blood (2011) 118 (21): 1874.

https://doi.org/10.1182/blood.V118.21.1874.1874

Published: 2011

Journal Articles

Final Results of the Phase II Trial of Single Agent Panobinostat (LBH589) in Relapsed or Relapsed/Refractory Waldenstrom Macroglobulinemia

Irene M. Ghobrial, MD, Ranjit Banwait, MA, Tiffany Poon, BS, Federico Campigotto, MS, Erica N Boswell, BS, Stacey Chuma, BSN, Janet Kunsman, NP, Amanda Donovan, BS, Meghan Bagshaw, Diane Warren, Kenneth C. Anderson, MD, Paul G. Richardson, MD, Edie Weller, PhD, Timothy J. Murphy, MD, FACP, Jeffrey Matous, MD

Blood (2011) 118 (21): 2706.

https://doi.org/10.1182/blood.V118.21.2706.2706

Published: 2011

Journal Articles

Phase I Trial of Everolimus and Rituximab or Everolimus, Bortezomib and Rituximab in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia

Irene M. Ghobrial, MD, Erica N Boswell, BS, Ranjit Banwait, MA, Tiffany Poon, BS, Amanda Donovan, BS, Stacey Chuma, BSN, Janet Kunsman, NP, Diane Warren, Meghan Bagshaw, Kenneth C. Anderson, MD, Paul G. Richardson, MD, Steven Treon, MD, PhD

Blood (2011) 118 (21): 2705.

https://doi.org/10.1182/blood.V118.21.2705.2705

Published: 2011

Journal Articles

The Role of Bortezomib-Containing Regimens in Improving Response in Patients with Waldenstrom Macroglobulinemia

Ranjit Banwait, MA, Edie Weller, PhD, Nitin Ropur, MD, Claudia E. Paba-Prada, MD, Lina Benajiba, Meghan Bagshaw, Steven P Treon, MD, PhD, Irene M. Ghobrial, MD

Blood (2011) 118 (21): 2713.

https://doi.org/10.1182/blood.V118.21.2713.2713

Published: 2011

Journal Articles

LNA Anti-MicroRNA-155: A Novel Therapeutic Strategy in Waldenstrom Macroglobulinemia and Chronic Lymphocytic Leukemia

Blood (2011) 118 (21): 2728.

https://doi.org/10.1182/blood.V118.21.2728.2728

Published: 2011

Journal Articles

MicroRNA-155 As a Potential Plasma Biomarker for Chronic Lymphocytic Leukemia and Waldenstrom Macroglobulinemia,

Christopher P. Rombaoa, Yong Zhang, PhD, Ranjit Banwait, MA, Yang Liu, PhD, Hai T Ngo, BS, Phong Quang, Abdel Kareem Azab, Bpharm, PhD, Feda Azab, BPharm, Patricia Maiso, PhD, Michaela Reagan, PhD, Antonio Sacco, BS, Aldo M Roccaro, MD, PhD, Jennifer R. Brown, MD, PhD, Irene M. Ghobrial, MD

Blood (2011) 118 (21): 3669.

https://doi.org/10.1182/blood.V118.21.3669.3669

Published: 2011

Journal Articles

Incidence of Peripheral Neuropathy in Waldenström Macroglobulinemia Patients At Diagnosis,

Claudia E. Paba-Prada, MD, Ranjit Banwait, MA, Steven Treon, MD, PhD, Irene M. Ghobrial, MD

Blood (2011) 118 (21): 3692.

https://doi.org/10.1182/blood.V118.21.3692.3692

Published: 2011

Journal Articles

Final Results of the Phase I/II Trial of Weekly Bortezomib In Combination with Temsirolimus (CCI-779) In Relapsed or Relapsed/Refractory Multiple Myeloma Specifically In Patients Refractory to Bortezomib

Blood (2010) 116 (21): 990.

https://doi.org/10.1182/blood.V116.21.990.990

Published: 2010

Journal Articles

Phase II Trial of Single Agent Panobinostat (LBH589) In Relapsed or Relapsed/Refractory Waldenstrom Macroglobulinemia

Irene Ghobrial, MD, Tiffany Poon, BS, Meghan Rourke, Stacey Chuma, BSN, Janet Kunsman, NP, Ranjit Banwait, Amy Sam, Diane Warren, Kenneth C. Anderson, Paul Richardson, M.D., Ph.D., Steven P. Treon, MD, PhD, Jeffrey Matous, MD

Blood (2010) 116 (21): 3952.

https://doi.org/10.1182/blood.V116.21.3952.3952

Published: 2010

Journal Articles

The Role of PET Scan Imaging In Waldenstrom Macroglobulinemia

Ranjit Banwait, Federico Campigotto, Edie Weller, Brianna Harris, Dilek Yarar, Aldo M. Roccaro, MD, PhD, Meghan Rourke, Renee Leduc, Xavier Leleu, MD, PhD, Irene M. Ghobrial, MD

Blood (2010) 116 (21): 4153.

https://doi.org/10.1182/blood.V116.21.4153.4153

Published: 2010

Journal Articles

Phase I Trial of Plerixafor and Bortezomib as a Chemosensitization Strategy In Relapsed or Relapsed/Refractory Multiple Myeloma

Irene Ghobrial, MD, Abdel Kareem A. Azab, PhD, BSPharm, Jacob P. Laubach, MD, MPP, Ranjit Banwait, Meghan Rourke, Phong Quang, Nikhil C. Munshi, MD, Robert L. Schlossman, MD, Stacey Chuma, BSN, Janet Kunsman, NP, Diane Warren, Amy Sam, Eric Still, Brittany Morgan, Kenneth C. Anderson, Paul G Richardson

Blood (2010) 116 (21): 1943.

https://doi.org/10.1182/blood.V116.21.1943.1943

Published: 2010

NARROW

Thrombocytopenia Associated with Increase in Disease Severity and Mortality in COVID-19 Patients

Final Results of the Phase I/II Study of Chemosensitization Using the CXCR4 Inhibitor Plerixafor in Combination with Bortezomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma

Final Results of Phase I/II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Combination with Bortezomib and Rituximab (RVR) in Relapsed or Refractory Waldenstrom Macroglobulinemia

Phase I/II Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy In Relapsed Or Relapsed/Refractory Multiple Myeloma

Mirna Expression Profiling and Proteomic Analysis Of Circulating Exosomes From Multiple Myeloma Patients

Extramedullary Disease In Waldenstrom’s Macroglobulinemia

Phase I/II Trial Of Everolimus, Bortezomib and Rituximab In Relapsed Or Relapsed/Refractory Waldenstrom's Macroglobulinemia

Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemia

Comparative miRNA Expression Profiling of Circulating Exosomes From MGUS and Smoldering Multiple Myeloma Patients

Phase I Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy in Relapsed or Relapsed/Refractory Multiple Myeloma

Final Results of the Phase II Trial of Single Agent Panobinostat (LBH589) in Relapsed or Relapsed/Refractory Waldenstrom Macroglobulinemia

Phase I Trial of Everolimus and Rituximab or Everolimus, Bortezomib and Rituximab in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia

The Role of Bortezomib-Containing Regimens in Improving Response in Patients with Waldenstrom Macroglobulinemia

LNA Anti-MicroRNA-155: A Novel Therapeutic Strategy in Waldenstrom Macroglobulinemia and Chronic Lymphocytic Leukemia

MicroRNA-155 As a Potential Plasma Biomarker for Chronic Lymphocytic Leukemia and Waldenstrom Macroglobulinemia,

Incidence of Peripheral Neuropathy in Waldenström Macroglobulinemia Patients At Diagnosis,

Final Results of the Phase I/II Trial of Weekly Bortezomib In Combination with Temsirolimus (CCI-779) In Relapsed or Relapsed/Refractory Multiple Myeloma Specifically In Patients Refractory to Bortezomib

Phase II Trial of Single Agent Panobinostat (LBH589) In Relapsed or Relapsed/Refractory Waldenstrom Macroglobulinemia

The Role of PET Scan Imaging In Waldenstrom Macroglobulinemia

Phase I Trial of Plerixafor and Bortezomib as a Chemosensitization Strategy In Relapsed or Relapsed/Refractory Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only